Clinical trial
Efficacy of SNX-1012 in the Treatment of Oral Mucositis
NCT00385515 · Mucosal Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00385515 |
|---|---|
| Title | Efficacy of SNX-1012 in the Treatment of Oral Mucositis |
| Official title | A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer |
| Lead sponsor | Mucosal Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stomatitis, Oral Mucositis |
| Intervention type | Drug |
| Interventions | SNX-1012 (meclocycline sulfosalicylate), placebo |
| Enrollment | 81 |
| Start date | Jun 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Oct 9, 2006 |
| Last update posted | May 7, 2009 |
| Countries | India, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: